Valuation: Bicycle Therapeutics plc

Market Cap 307M 263M 247M 225M 425M 29.29B 430M 2.91B 1.13B 14.78B 1.15B 1.13B 48.94B P/E 2026 *
-1.69x
P/E 2027 * -1.88x
Enterprise Value -206M -176M -165M -151M -284M -19.59B -287M -1.95B -758M -9.89B -772M -755M -32.74B EV / Sales 2026 *
-11.7x
EV / Sales 2027 * -14.4x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day+1.39%
1 week+10.03%
Current month+13.73%
1 month+13.44%
3 months-3.52%
6 months-23.39%
Current year-37.99%
1 week 4.04
Extreme 4.035
4.51
1 month 3.74
Extreme 3.745
4.51
Current year 3.74
Extreme 3.745
7.34
1 year 3.74
Extreme 3.745
9.16
3 years 3.74
Extreme 3.745
28.67
5 years 3.74
Extreme 3.745
62.08
10 years 3.74
Extreme 3.745
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/7/26 Free

Chief Technology Officer

60,000 0.1580%
15/7/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%+10.03%-38.34%-81.30% 307M
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.87%+3.05%+51.09%+92.59% 64.17B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-2.78%+5.95%+55.58%+12.15% 27.33B
-0.68%+1.39%+38.32%-17.03% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-0.57%+7.19%+538.65% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
Average +0.97%+5.02%+49.90%+169.12% 28.87B
Weighted average by Cap. +1.49%+3.32%+55.78%+155.19%

Financials

2026 *2027 *
Net sales 17.53M 15.02M 14.08M 12.86M 24.27M 1.67B 24.51M 166M 64.64M 843M 65.83M 64.4M 2.79B 6.69M 5.73M 5.37M 4.91M 9.26M 638M 9.35M 63.35M 24.66M 322M 25.11M 24.57M 1.07B
Net income -172M -147M -138M -126M -238M -16.4B -240M -1.63B -634M -8.28B -646M -632M -27.41B -175M -150M -141M -128M -242M -16.69B -245M -1.66B -646M -8.42B -657M -643M -27.89B
Net Debt -513M -439M -412M -376M -710M -48.89B -717M -4.86B -1.89B -24.67B -1.93B -1.88B -81.68B -403M -346M -324M -296M -558M -38.45B -564M -3.82B -1.49B -19.4B -1.51B -1.48B -64.25B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
25/08/26 US$4.390 +1.39% 209,895
24/08/26 US$4.330 -0.92% 144,091
21/08/26 US$4.370 +3.07% 480,746
20/08/26 US$4.240 +2.42% 374,171
19/08/26 US$4.140 +3.76% 346,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
4.390USD
Average target price
9.500USD
Spread / Average Target
+116.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock